Latest Insider Transactions at Avrobio, Inc. (AVRO)
This section provides a real-time view of insider transactions for Avrobio, Inc. (AVRO). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of AVROBIO, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of AVROBIO, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
May 14
2024
|
Braden Michael Leonard |
BUY
Open market or private purchase
|
Indirect |
296,882
+5.86%
|
$296,882
$1.3 P/Share
|
May 13
2024
|
Braden Michael Leonard |
BUY
Open market or private purchase
|
Indirect |
469,753
+5.12%
|
$469,753
$1.25 P/Share
|
Feb 05
2024
|
Azadeh Golipour Chief Technology Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
12,232
-17.96%
|
$12,232
$1.2 P/Share
|
Feb 05
2024
|
Steven Avruch Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
10,812
-32.93%
|
$10,812
$1.2 P/Share
|
Feb 05
2024
|
Erik Ostrowski Interim CEO, President and CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
13,099
-30.91%
|
$13,099
$1.2 P/Share
|
Feb 05
2024
|
Essra Ridha Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
16,953
-51.63%
|
$16,953
$1.2 P/Share
|
Feb 01
2024
|
Azadeh Golipour Chief Technology Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
37,334
+35.41%
|
-
|
Feb 01
2024
|
Steven Avruch Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
32,834
+50.0%
|
-
|
Feb 01
2024
|
Erik Ostrowski Interim CEO, President and CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
40,084
+48.61%
|
-
|
Feb 01
2024
|
Essra Ridha Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
32,834
+50.0%
|
-
|
Jun 12
2023
|
Azadeh Golipour Chief Technology Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,574
-7.7%
|
$5,574
$1.2 P/Share
|
Jan 24
2023
|
Geoffrey Mackay President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
45,999
+19.66%
|
$0
$0.91 P/Share
|
Dec 28
2022
|
Geoffrey Mackay President & CEO |
BUY
Bona fide gift
|
Indirect |
245,123
+35.51%
|
-
|
Dec 28
2022
|
Geoffrey Mackay President & CEO |
SELL
Bona fide gift
|
Direct |
245,123
-63.32%
|
-
|
Dec 23
2022
|
Geoffrey Mackay President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
142,013
+26.84%
|
$0
$0.41 P/Share
|
Jul 07
2021
|
Philip J. Vickers Director |
BUY
Open market or private purchase
|
Direct |
4,800
+50.0%
|
$38,400
$8.35 P/Share
|
Feb 17
2021
|
Phillip B. Donenberg Director |
BUY
Open market or private purchase
|
Direct |
2,000
+50.0%
|
$22,000
$11.71 P/Share
|
Dec 24
2020
|
Geoffrey Mackay President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
100,000
+28.98%
|
$0
$0.41 P/Share
|